Change in Cell Death Markers During <sup>177</sup>Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma

Elgström, Erika; Ljungberg, Otto; Eriksson, Sophie E.; Örbom, Anders; Strand, Sven‐Erik; Ohlsson, Tomas; Nilsson, Rune; Tennvall, Jan

doi:10.1089/cbr.2013.1576

Cited by 3 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These were mainly involved in processes of infiltration of immune cells and angiogenesis. The presence of chemokines promoting the recruitment of leukocytes corresponded with earlier studies showing infiltration of neutrophils, 9 T cells, and macrophages 10 in this tumor model. The cytokine pattern was considered to be neither pro-inflammatory (described as consisting of IL-6, IL-17, IFN-γ, TNF-α, IL-1α/β among others) nor anti-inflammatory (containing cytokines like IL-1ra, IL-14, IL-5, IL-10, IL-11, IL-13).…”

Section: Discussionsupporting

confidence: 89%

“…9 The tumors were also infiltrated by neutrophils and lymphocytes. 9 Analysis of immune cell markers demonstrated that T cells and macrophages augmenting tumor rejection were present to a higher extent than those associated with immune tolerance, and that the number of immune cells decreased as a result of the treatment. 10 After treatment, approximately half of the animals in the syngeneic rat model developed metastases within the follow-up period of 100 days.…”

Section: Introductionmentioning

confidence: 99%

“…8 Analysis of tumors during regression has shown that tumors transformed from dense growth of tumor cells to the formation of granulation tissue with ongoing cell death located mainly in the peripheral parts of the tumor. 9 The tumors were also infiltrated by neutrophils and lymphocytes. 9 Analysis of immune cell markers demonstrated that T cells and macrophages augmenting tumor rejection were present to a higher extent than those associated with immune tolerance, and that the number of immune cells decreased as a result of the treatment.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cytokine evaluation in untreated and radioimmunotherapy-treated tumors in an immunocompetent rat model

2017

Self Cite

View full text Add to dashboard Cite

The tumor microenvironment can act so as to stimulate or reject tumor cells. Among the determining factors are cytokines produced, for example, by infiltrating immune cells, tumor cells, and fibroblasts. External radiotherapy has been shown to be able to activate an immune response against tumor cells with cytokine signaling as an important part of the activation. The aim of this study was to evaluate the cytokines present in the tumor microenvironment and whether the cytokine profile changed during tumor regression induced by radioimmunotherapy with the beta emitter 177 Lu. Immunocompetent rats with colon carcinoma tumors were injected with 400 MBq/kg 177 Lu-mAb, and the tumors were excised after 1, 2, 3, 4, 6, or 8 days post injection (4 rats/day on days 1-6 and 8 rats on day 8). Tumors from 10 untreated rats were used as control tissue. The tumors were divided into half: one half was prepared for cytokine analysis with a cytokine array kit and the other half was used for histological analysis. A total of 18 of the 29 cytokines evaluated were detected in this tumor model, and the majority of these act in a pro-inflammatory manner or stimulate the infiltration of immune cells. The differences between treated tumors and control tumors were small, thus the cytokine profile in the untreated tumors did not transfer to an anti-inflammatory profile during tumor regression induced by radioimmunotherapy with 177 Lu. Histological evaluation demonstrated a heterogeneous pattern of ongoing cell death and the formation of granulation tissue.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cytokine evaluation in untreated and radioimmunotherapy-treated tumors in an immunocompetent rat model

2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…The histological features of untreated tumors and tumors from animals treated with RIT have been described previously, showing that the fraction of granulation tissue increased in tumors treated with RIT (maximum at 4 days p.i. ), and that the granulation tissue matured into fibrous tissue which increased throughout the study period [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model

et al. 2015

Self Cite

View full text Add to dashboard Cite

BackgroundImmune cells within the tumor can act either to promote growth or rejection of tumor cells. The aim of the present study was to evaluate immune cell markers (number and localization) within the tumor before and during rejection due to radioimmunotherapy, to determine whether there is a change in markers related to rejection and/or tolerance of the tumor cells.MethodsThirty immunocompetent rats were inoculated with syngeneic rat colon carcinoma cells and 13–14 days later 21 of these rats were treated with 400 MBq/kg of 177Lu-DOTA-BR96 monoclonal antibodies. The treated animals were sacrificed and dissected 1, 2, 3, 4, 6, and 8 days post-injection in groups of three animals per day (6 animals on day 8); while the nine untreated animals were sacrificed and dissected on day 0. Paraffin sections were used for immunohistochemical staining of CD2, CD3, CD8α, CD68, and CD163 antigens. Positive cells were counted within: vital tumor cell areas, necrotic areas, granulation tissue surrounding and between the tumor cell areas. The change in the number of positive cells over time in tumors treated with radioimmunotherapy in the same location was evaluated with linear regression models. The number of positive cells in various locations and the number of various antigen-positive cells within the same location were also evaluated over time using box plots.ResultsThere were a higher number of cells expressing immune cell markers in granulation tissue compared with vital tumor cell areas. Cells expressing markers decreased during radioimmunotherapy, and T-cell markers decreased more than macrophage markers in tumors treated with radioimmunotherapy. The expression of CD8α was higher than that of the other T-cell markers evaluated (CD3 and CD2), which could be explained by the additional expression of CD8α by natural killer (NK) cells and a subset of dendritic cells (DCs). The expression of CD68 (all macrophages, DCs, and neutrophils) tended to be higher than that of CD163 (pro-tumor macrophages).ConclusionsIn this model, we demonstrated a higher number of positive cells for immune cell markers related to augmenting the immune rejection than immune tolerance of tumor cells in tumors and a decrease in markers during radioimmunotherapy.

show abstract

“…In the present study, we administered an activity of 400 MBq/kg body weight, which results in mean absorbed dose rates of approximately 0.2 to 0.6 Gy/h at the maximal uptake, 24 h p.i. [ 30 ]. To the best our knowledge, no study has evaluated the effect of CD8 lymphocytes on the therapeutic outcome of RIT.…”

Section: Discussionmentioning

confidence: 99%

Role of CD8-positive cells in radioimmunotherapy utilizing 177Lu-mAbs in an immunocompetent rat colon carcinoma model

et al. 2015

Self Cite

View full text Add to dashboard Cite

BackgroundCD8-positive cells might play a crucial role in the therapeutic response to radiation, which has however not been investigated in radioimmunotherapy (RIT). The aim of this study was to evaluate whether cytotoxic T cells affect the response of established tumors and, above all, if they delay or prevent the development of distant metastases after RIT, using an immunocompetent syngeneic rat colon carcinoma model.MethodsThe cytotoxic T cells were depleted in 15 rats by anti-CD8 before the injection of the radioimmunoconjugate (400 MBq/kg body weight 177Lu-BR96, which binds to the tumor-associated antigen Lewis Y). Fifteen other rats were treated with RIT only. Both groups were followed for 99 days. Blood samples were collected at least once weekly, and tumors were monitored twice weekly.ResultsTwenty-nine of the 30 animals exhibited local complete response. The non-responder was treated with anti-CD8 and RIT but succumbed later due to metastases. Five animals in the group given anti-CD8 + RIT were sacrificed due to metastatic disease, and 4 additional animals were found to have metastases at autopsy. In the group given RIT, 4 animals developed metastatic disease, but no metastases were found in the remaining 11 animals at autopsy. Thus, at the end of the study, 6 animals in the anti-CD8 + RIT group were free from metastases, while 11 were free from metastases in the group receiving RIT.CD3+CD4−CD8+ lymphocytes were consistently depleted by the anti-CD8 treatment. The myelosuppression was otherwise similar in the two groups. The initial depletion of CD8-positive cells in our syngeneic rat colon carcinoma model resulted in a higher frequency of animals developing metastases.ConclusionsDepletion of CD8-positive cells during RIT in an immunocompetent rat tumor model might influence the number of animals developing metastases, indicating that the immune system may be important in the long-term outcome of RIT.

show abstract

Change in Cell Death Markers During ¹⁷⁷Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma

Abstract: Following radioimmunotherapy in an immunocompetent syngeneic colon carcinoma model, tumor cells did not only die through caspase-3-dependent apoptosis, but also by other mechanisms.

Cited by 3 publications

References 40 publications

Cytokine evaluation in untreated and radioimmunotherapy-treated tumors in an immunocompetent rat model

Cytokine evaluation in untreated and radioimmunotherapy-treated tumors in an immunocompetent rat model

Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model

Role of CD8-positive cells in radioimmunotherapy utilizing 177Lu-mAbs in an immunocompetent rat colon carcinoma model

Contact Info

Product

Resources

About

Change in Cell Death Markers During 177Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma

Abstract: Following radioimmunotherapy in an immunocompetent syngeneic colon carcinoma model, tumor cells did not only die through caspase-3-dependent apoptosis, but also by other mechanisms.

Cited by 3 publications

References 40 publications

Cytokine evaluation in untreated and radioimmunotherapy-treated tumors in an immunocompetent rat model

Cytokine evaluation in untreated and radioimmunotherapy-treated tumors in an immunocompetent rat model

Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model

Role of CD8-positive cells in radioimmunotherapy utilizing 177Lu-mAbs in an immunocompetent rat colon carcinoma model

Contact Info

Product

Resources

About

Change in Cell Death Markers During ¹⁷⁷Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma